Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04518059 · ClinicalTrials.gov registry record
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 184
- Enrollment target
NCT04518059: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT04518059 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04518059 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) or no parkinsonism at all (control).
Primary Outcome
Alpha-synuclein will be measured by RT-QuIC and sPMCA
Interventions
- PROCEDURE punch skin biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2025-05-31 |
What the finished NCT04518059 record still lists
NCT04518059 is an observational study that tracks outcomes without assigning an intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which punch skin biopsy is the first listed.
NCT04518059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04518059 about?
NCT04518059 is a clinical study titled "Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism". The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia w...
What is the current status of trial NCT04518059?
This trial is currently completed. The enrollment target is 184 participants. The study started on 2019-03-12. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT04518059?
The interventions under investigation include: punch skin biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04518059?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI